Improving Care for Cancer Survivors

By Julie Grisham,

Wednesday, June 24, 2015

Robert Sidlow

In this interview, Robert Sidlow discusses Memorial Sloan Kettering’s efforts to improve patient access to supportive care, better integrate these services throughout the course of patients’ care, and stimulate new research and standards of care through the creation of the new Division of Survivorship and Supportive Care.

  • Supportive care services have become a key component of cancer care.
  • Survivorship is a growing focus of research as patients live longer after cancer.
  • New methods can measure patient experiences during and after treatment.

In February 2015, experienced physician and hospital administrator Robert Sidlow joined Memorial Sloan Kettering as Head of our newly created Division of Survivorship and Supportive Care within the Department of Medicine. The division — which brings together internal medicine, hospital medicine, geriatrics, integrative medicine, employee health and wellness, urgent care, and palliative care under one umbrella — aims to improve patient access to supportive care, better integrate these services throughout the course of patients’ care, and stimulate new research and standards of care.

We spoke with Dr. Sidlow recently about his background and his plans for the new division.

Tell us about the Division of Survivorship and Supportive Care.

While MSK has long had services to address survivorship and supportive care for our patients, they have grown organically in importance, scope, and size over the years — yet they have largely remained separate from one another. Since supportive care and survivorship all are now recognized as core standards of care for people with cancer and are vital for supporting the patient throughout the entire course of treatment and beyond, it made sense to bring these practitioners under one umbrella and focus our clinical and research efforts together.

As cancer becomes more of a chronic disease, with doctors often able to offer patients multiple types of treatment if the cancer comes back, patients’ needs for supportive care may change over the long term. Because of scientific advances that identify the molecular causes of disease, many patients now have access to new therapies, and many of these treatments have side effects.

We are living in an extraordinary time with regard to the way we’re treating cancer, and MSK is pushing the envelope of what is possible. We have to be there to support the patient through his or her entire journey, whatever the outcome. It is only by understanding the whole person in a larger context that we can truly support our patients and ease their burden in the fundamental ways — physically, psychologically, and spiritually — that they need us to. This new division is uniquely poised to lead the way.

Back to top

What kind of work is the division undertaking?

The chiefs of the different services within the division are meeting regularly with each other, and we are establishing forums to stimulate conversations among the different groups and across all of MSK. A monthly research “Works in Progress” seminar enables team members to share their findings and promotes investigative collaboration across the organization.

Regarding research, issues around quality of life and patient experience — as seen from the patient perspective — are becoming increasingly important. There’s been a lot of study of the prevalence of different symptoms in patients undergoing cancer treatment — not only physical symptoms but also psychological and existential symptoms.

One study that recently came out looking at patients with breast cancer found that worry and difficulty sleeping are two of the most prevalent symptoms. In addition, fatigue, pain, change in food taste, lack of ability to concentrate, and sexual problems are all common.

All of these types of symptoms permeate the experiences that people have while being treated for cancer and are very important to address. The focus of cancer research has expanded beyond questions such as “did the tumor grow or shrink?” and “how much longer did the patient live?” We are now trying to understand if, and how, our cancer treatments are affecting the quality of life of our patients. This is a fundamental change. 

Back to top

How do you measure quality of life?

Obviously this is not as simple as using a thermometer to measure someone’s temperature. However, there is a body of research that addresses the challenge of measuring the personal experience of being a cancer patient, usually using standardized surveys that ask patients what they’re thinking and feeling. Important outcomes such as pain, fatigue, how well the patient is able to function in daily life, and emotional and spiritual distress are called “patient-reported outcomes” and are becoming increasingly important elements of research into new drugs.

Back to top

Why has looking at cancer care from a quality-of-life perspective become more important?

Over the past few decades, we have developed many good therapies to keep patients alive longer, but those therapies come with their own toxicities. Some of the side effects from cancer treatment can last years after treatment is completed and can greatly diminish a patient’s quality of life.

In addition, because of other improvements in healthcare, people are living longer lives. As a result, the population of cancer patients over age 80 is expected to swell over the next few decades. As MSK continues to push the envelope on the treatment of geriatric patients with cancer, we have to figure out how to balance the risks and benefits of various treatments in this vulnerable population. 

Back to top

How did you get interested in this field?

I’m a general internist by training, have chaired a department of medicine, and have run a palliative medicine service. This broad experience gives me the advantage of perspective when it comes to caring for patients — something I call using the “macroscope.” I can get into the nitty-gritty details of patient care, but I can also come up and ask the bigger questions about the whole patient. In addition, my experience as a hospital administrator helps me know what it takes to provide quality and safe care both to patients and to the overall healthcare system writ large.

Back to top

What do you hope to accomplish now that you’re here?

I’m so grateful that MSK leadership has brought me here to head this new division. The patient-centered culture of MSK is unique, and it allows us to pursue research and hard-core science while taking care of our patients in a compassionate manner. My vision is to integrate the core elements of the division’s care as a standard part of cancer therapy for all MSK patients, and eventually at all locations. Scaling this effort across the institution will be challenging, but we’ll also be setting the standard for what it means to be a comprehensive cancer center. What MSK does really matters.

Back to top


I a Brazilian that had removal of a recto cancer after radio and quimio before surgery and quimio after. Removal was done 1.5 years ago. 2 CT done are OK. Question now is not go to bathroom 20 times a day. How to reduce this number?

Carlos, we are not able to provide personal medical advice on our blog. We recommend you speak with members of your healthcare team about this. Thank you for your comment.

I have prostate cancer that has mestastized to my bones. I have been on five different drugs and all have failed. what is my next option?currently my psa is 275.

I had a prostectomy in 2006 and returned for examinations and PSA until two years ago. I missed an appointment and never rescheduled. I would like to make an appointment for a PSA and exam.I am feeling fine. I know I can get a PSA test elsewhere, but would like to remain associated with Sloan Kettering. How do I make an appointment?

I am a former colleague of Dr. Sidlow when he was HMD at Compassionate Care Hospice in the Bronx. I am trying to get a contact email for him at MSKCC- can you provide? Many thanks

Dear James, unfortunately we are not able to give out our staff's email addresses on our blog. Please contact his office directly by calling our main number at 212-639-2000. Thank you for reaching out to us.


My dad is 61 years old and is suffering from Mylofibrosis. He is been prescribed Jakavi by Novartis but after 6 months of use it provoked Tuberculosis and compromised chronic liver disease without hepatitis. Kindly guide if there is any suitable treatment option for him.

Zubia, we're sorry to hear your father is going through this. If he would like to arrange for a consultation with our experts in bone marrow disease, he can call 800-525-2225 during regular business hours or go to for more information on making an appointment. Thank you for your comment.

Add new comment

We welcome your questions and comments. While we share many of them with our world-class doctors and researchers, we regret that in order to protect your privacy, we are not able to make personal medical recommendations on this forum, nor do we publish comments that contain your personal information. If you would like to consult with an MSK doctor, we encourage you to make an appointment at 800-525-2225 or request an appointment online.

Your email address is kept private and will not be shown publicly.